Home > Research > Publications & Outputs > Tunable emissive Ir(III) benzimidazole-quinolin...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds. / Redrado, Marta; Miñana, Miriam; Coogan, Michael et al.
In: ChemMedChem, Vol. 17, No. 18, e202200244, 16.09.2022.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Redrado, M, Miñana, M, Coogan, M, Gimeno, MC & Fernández-Moreira, V 2022, 'Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds', ChemMedChem, vol. 17, no. 18, e202200244. https://doi.org/10.1002/cmdc.202200244

APA

Redrado, M., Miñana, M., Coogan, M., Gimeno, M. C., & Fernández-Moreira, V. (2022). Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds. ChemMedChem, 17(18), Article e202200244. https://doi.org/10.1002/cmdc.202200244

Vancouver

Redrado M, Miñana M, Coogan M, Gimeno MC, Fernández-Moreira V. Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds. ChemMedChem. 2022 Sept 16;17(18):e202200244. Epub 2022 Jul 13. doi: 10.1002/cmdc.202200244

Author

Redrado, Marta ; Miñana, Miriam ; Coogan, Michael et al. / Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds. In: ChemMedChem. 2022 ; Vol. 17, No. 18.

Bibtex

@article{25e9e849b49c44e291133d842c7267e9,
title = "Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds",
abstract = "Bioactive and luminescent cyclometallated Ir(III) complexes [Ir(ppy) 2 L1 ]Cl ( 1 ) and [Ir(ppy) 2 L2 ]Cl ( 2 ) containing a benzimidazole derivative ( L1 / L2 ) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2 , rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 ( 1 ) and 0.36 ( 2 ), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC 50 values in the nanomolar range (0.3 ± 0.09 μM ( 1 ) and 0.26 ± 0.14 μM ( 2 )) and pointing them as good PSs candidates for photodynamic therapy via 1 O 2 generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.",
keywords = "Theranostics, Iridium, singlet oxygen (1O2)",
author = "Marta Redrado and Miriam Mi{\~n}ana and Michael Coogan and Gimeno, {M. Concepci{\'o}n} and Vanesa Fern{\'a}ndez-Moreira",
year = "2022",
month = sep,
day = "16",
doi = "10.1002/cmdc.202200244",
language = "English",
volume = "17",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "18",

}

RIS

TY - JOUR

T1 - Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds

AU - Redrado, Marta

AU - Miñana, Miriam

AU - Coogan, Michael

AU - Gimeno, M. Concepción

AU - Fernández-Moreira, Vanesa

PY - 2022/9/16

Y1 - 2022/9/16

N2 - Bioactive and luminescent cyclometallated Ir(III) complexes [Ir(ppy) 2 L1 ]Cl ( 1 ) and [Ir(ppy) 2 L2 ]Cl ( 2 ) containing a benzimidazole derivative ( L1 / L2 ) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2 , rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 ( 1 ) and 0.36 ( 2 ), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC 50 values in the nanomolar range (0.3 ± 0.09 μM ( 1 ) and 0.26 ± 0.14 μM ( 2 )) and pointing them as good PSs candidates for photodynamic therapy via 1 O 2 generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.

AB - Bioactive and luminescent cyclometallated Ir(III) complexes [Ir(ppy) 2 L1 ]Cl ( 1 ) and [Ir(ppy) 2 L2 ]Cl ( 2 ) containing a benzimidazole derivative ( L1 / L2 ) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2 , rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 ( 1 ) and 0.36 ( 2 ), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC 50 values in the nanomolar range (0.3 ± 0.09 μM ( 1 ) and 0.26 ± 0.14 μM ( 2 )) and pointing them as good PSs candidates for photodynamic therapy via 1 O 2 generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.

KW - Theranostics

KW - Iridium

KW - singlet oxygen (1O2)

U2 - 10.1002/cmdc.202200244

DO - 10.1002/cmdc.202200244

M3 - Journal article

VL - 17

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 18

M1 - e202200244

ER -